Bartłomiej Grala

Bartłomiej Grala

Auto-generated profile, based on publicly available information

Bartłomiej Grala

Department of Pathology, Military Institute of Medicine, Szaserów 128 Street, 04-141 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2013 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MSMarta Smoter
Marta Smoter
LBLubomir Bodnar
Lubomir Bodnar
BGBartlomiej Grala
Bartlomiej Grala
RSRafał Stec
Rafał Stec
KZKrystyna Zieniuk
Krystyna Zieniuk
CSCezary Szczylik
Cezary Szczylik
The aim of the study was to evaluate predictive and prognostic significance of microtubule-associated protein Tau in epithelial ovarian cancer (EOC) patients treated with paclitaxel and platinum-based chemotherapy.

7 October 2009 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RSRafał Stec
Rafał Stec
BGBartłomiej Grala
Bartłomiej Grala
Michał MączewskiMichał Mączewski
Michał Mączewski
LBLubomir Bodnar
Lubomir Bodnar
CSCezary Szczylik
Cezary Szczylik
Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.

25 June 2014 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
RDRENATA DUCHNOWSKA
RENATA DUCHNOWSKA
EZEwa Ziajka
Ewa Ziajka
AGAgnieszka Góralska
Agnieszka Góralska
BGBartłomiej Grala
Bartłomiej Grala
Pyoderma gangrenosum is a rare clinical entity of poorly understood pathogenesis, characterized by rapidly progressing skin necrosis. In around half of patients pyoderma gangrenosum is a manifestation of underlying systemic diseases, such as rheumatoid arthritis, inflammatory bowel disease or myeloproliferative disorders. There have been very few reports on the association of pyoderma gangrenosum with solid malignancies.